What You Need to Know
Aegis is pleased to offer industry-leading testing options to allow providers the opportunity to more completely understand an individual’s drug use pattern, and facilitate more informed care and harm reduction measures. New Psychoactive Substances (NPS) are compounds designed to mimic common illicit or prescription drugs while evading regulation and routine testing methods. They are also known as “novel psychoactive substances,” “designer drugs,” or “research chemicals.”
Cychlorphine, also known as N‑propionitrile chlorphine, is a novel synthetic opioid belonging to the “orphine” subclass of benzimidazolone‑derived opioids. Aegis began offering testing for this drug in the Designer Opioid panel in urine and oral fluid in May 2025.
N-Propionitrile Chlorphine (Cychlorphine) Detection by State
State Detection by Color
States in Dark Orange: Tested and Detected
States in Light Orange: Tested and Not Detected
States in White: No Samples Received for Testing
N-Propionitrile Chlorphine (Cychlorphine) News
Aegis Sciences Corporation’s, Dr. Joshua Schrecker, Sr. Director, Clinical Affairs, was recently interviewed by Lexi Wilson from WKRN News 2 about N-Propionitrile Chlorphine, also known as Cychlorphine, a highly potent synthetic opioid entering into the market.
“When we see it, it’s often times in a pretty complex mixture of drugs, and that’s really where the risk is,” Dr. Schrecker said.
About N-Propionitrile Chlorphine (Cychlorphine)
- Approximately 10× more potent than fentanyl based on in vitro pharmacology data.
- Aegis has identified cychlorphine in samples from Arkansas, California, Illinois, Indiana, Maine, Maryland, Massachusetts, Missouri, New Hampshire, Ohio, Tennessee, and West Virginia (reported as of 3/13/2026).
- Cychlorphine may be ingested alongside other opioids or designer opioids, stimulants, or benzodiazepines, enhancing the risk for polydrug toxicity and overdose.
- Multiple doses of naloxone may be required to reverse an overdose, and additional emergency care and airway support may be required.
- Testing for cychlorphine and other designer opioids and NPS helps clinicians monitor for high-risk substance use and polysubstance exposure.
